Skip to content
Peptigraph home

TRIUMPH-2: Retatrutide Phase 3 trial (NCT05929079)

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
1,152
actual
Start
11 Jul 2023 (actual)
Primary completion
16 Jun 2026 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05929079 study arms
ArmTypeInterventionsDescription
Retatrutide Dose 1ExperimentalDrug: RetatrutideParticipants will receive retatrutide subcutaneously (SC).
Retatrutide Dose 2ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
Retatrutide Dose 3ExperimentalDrug: RetatrutideParticipants will receive retatrutide SC.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will receive placebo.
Endpoints

Primary endpoint

NCT05929079 primary outcomes
MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 80
Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 SubsetBaseline, Week 80
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05929079 secondary outcomes
MeasureTime frame
Change from Baseline in Body Mass Index (BMI)Baseline, Week 80
Change from Baseline in Waist CircumferenceBaseline, Week 80
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 80
Change from Baseline in Diastolic Blood Pressure (DBP)Baseline, Week 80
Percent Change from Baseline in Total CholesterolBaseline, Week 80
Percent Change from Baseline in TriglyceridesBaseline, Week 80
Change from Baseline in Hemoglobin (A1c) HbA1c %Baseline, Week 80
Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Physical Functioning Domain ScoreBaseline, Week 80
Change from Baseline in Fasting GlucoseBaseline, Week 80
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)Baseline through Week 80
Percent Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 SubsetBaseline, Week 80
A Hierarchical Combination of Functional Outcomes of Sleep Questionnaire (FOSQ) 10 score, FOSQ Vigilance Domain Score, and FOSQ Activity Level Domain Score for GSA2 SubsetBaseline to Week 80
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

TRIUMPH-2 in adults with obesity and type 2 diabetes

Participants were randomised 1:1:1:1 to placebo or retatrutide 4, 9 or 12 mg, with week 80 bodyweight change as the primary endpoint for 9 and 12 mg.[2]

Mean bodyweight change was -11.9% on 4 mg, -16.8% on 9 mg and -18.8% on 12 mg, against -5.1% on placebo.[2]

Permanent discontinuation due to adverse events or death was 12% on 9 mg and 8% on 12 mg, compared with 4% on 4 mg and 5% on placebo.[2]

Diarrhoea occurred in 27%, 34% and 34% of the three retatrutide groups against 13% on placebo.[2]

Sources

  1. 1A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026

Found an error? Report a correction.